Study Indicates Significant Improvement in Condition After Treatment with Nano-Catalytic SilverSol Technology

American Biotech Labs, developer of a new class of products based on the company's patented nano-catalytic SilverSol Technology(TM), today announced that a preliminary study of the effect of the company's ASAP 10 treatment on HIV-positive individuals has been published in the first issue of the Journal of the Science of Healing Outcomes (JSHO; http://www.thejsho.com/pdf/Effect.pdf). JSHO is a scholarly health journal that publishes compelling new medical research data and reports.

The study was conducted over four months with seven HIV-positive patients, each of whom was administered 15 ml of ABL ASAP 10 ppm (parts per million) four times daily. As a result of the ABL treatment, "Clinically, (the patients) were 100 percent fit and were feeling much better after the treatment period," said Dr. B.M. Hegde, world-renowned cardiologist and editor of JSHO.

During the course of the therapy, the patients experienced an average body weight gain of eight kilograms (17.6 pounds) and an average T-lymphocyte count increase of 180 per micro-liter (39.52 percent).

One of the study's most significant findings, said Hegde, was the effect of ABL ASAP on HIV, the AIDS-causing virus. "Our recent laboratory work of the effect of nano silver in vitro on the... virus did show that the nanosilver particles could bind to (HIV) and could potentially block the viral entry into cells, eventually destroying the virus."

Hegde added, "Now that we have the laboratory results of the drug's efficacy and safety, we are planning a large scale controlled study of the application to HIV positive individuals in the near future."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit